RIGL Rigel Pharmaceuticals Inc.

2.37
+0.05  (+2%)
Previous Close 2.32
Open 2.32
Price To Book 3.59
Market Cap 396196467
Shares 167,171,505
Volume 2,057,631
Short Ratio
Av. Daily Volume 1,585,823

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released April 3, 2018. Primary endpoint not met.
Fostamatinib
IgA nephropathy
Phase 2 trial did not meet endpoints
R348
Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)
Approved April 17, 2018.
Tavalissetm (Fostamatinib)
Immune Thrombocytopenic Purpura (ITP)
Phase 3 trial to commence 1H 2019.
Fostamatinib
Autoimmune hemolytic anemia (AIHA)
Phase 1 initial data due 2H 2019.
R835
Autoimmune and inflammatory diseases

Latest News

  1. If You Had Bought Rigel Pharmaceuticals (NASDAQ:RIGL) Stock A Year Ago, You'd Be Sitting On A 40% Loss, Today
  2. Here's Why Rigel Pharmaceuticals Gained 17.3% in March
  3. Rigel Welcomes Jane Wasman to Board of Directors
  4. Is Rigel Pharmaceuticals, Inc.’s (NASDAQ:RIGL) CEO Overpaid Relative To Its Peers?
  5. Edited Transcript of RIGL earnings conference call or presentation 28-Feb-19 10:00pm GMT
  6. Rigel Pharmaceuticals (RIGL) Q4 2018 Earnings Conference Call Transcript
  7. Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
  8. Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results
  9. Is Rigel Pharmaceuticals a Buy?
  10. Market Trends Toward New Normal in SeaWorld Entertainment, Rigel Pharmaceuticals, Guidewire Software, Editas Medicine, Jones Energy, and Rexahn Pharmaceuticals — Emerging Consolidated Expectations, Analyst Ratings
  11. Rigel Rises On European Marketing Agreement For Autoimmune Drug
  12. 4 Healthcare Stocks Making Moves On Wednesday (1/23/19)
  13. Rigel Pharmaceuticals stock up 9% after announcing licensing agreement with Grifols
  14. Rigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
  15. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL): When Will It Breakeven?
  16. Rigel Pharmaceuticals Provides Business Update
  17. Rigel to Present at the 37th Annual J.P. Morgan Healthcare Conference
  18. Rigel Pharmaceuticals, Inc. (RIGL): Hedge Fund Sentiment Unchanged
  19. Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved
  20. Rigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City